A retrospective analysis of 32 patients with ROS-1 mutated NSCLC demonstrated median PFS of 9.1 months in a heavily pre-treated population, and included patients up to 78 years, but again age-specific outcomes were not reported [41]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.